Drug intelligence / Profile preview

YP05002

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

YP05002 is an investigational small molecule drug being developed primarily by YaoPharma for the treatment of obesity and weight management. It is currently in Phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The precise mechanism of action of YP05002 has not been disclosed in published literature or clinical trial records. It is considered a new molecular entity and is not currently approved for any indication[1][3][5][9].

Other names: YP05002YP-05002YP 05002

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on YP05002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YP05002.

Explore the full profile